11,116 Shares in Mereo BioPharma Group plc (NASDAQ:MREO) Acquired by Jump Financial LLC

Jump Financial LLC bought a new position in shares of Mereo BioPharma Group plc (NASDAQ:MREO) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,116 shares of the company’s stock, valued at approximately $39,000.

Other large investors have also added to or reduced their stakes in the company. State Street Corp acquired a new stake in Mereo BioPharma Group during the third quarter worth approximately $195,000. Sheets Smith Investment Management acquired a new stake in Mereo BioPharma Group in the fourth quarter valued at approximately $59,000. Walleye Capital LLC acquired a new stake in Mereo BioPharma Group in the fourth quarter valued at approximately $454,000. PFG Investments LLC grew its stake in Mereo BioPharma Group by 132.0% in the fourth quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock valued at $138,000 after acquiring an additional 22,433 shares during the period. Finally, HealthInvest Partners AB grew its stake in Mereo BioPharma Group by 95.0% in the fourth quarter. HealthInvest Partners AB now owns 390,000 shares of the company’s stock valued at $1,373,000 after acquiring an additional 190,000 shares during the period. Institutional investors and hedge funds own 62.83% of the company’s stock.

Analyst Upgrades and Downgrades

MREO has been the subject of a number of research reports. JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a research note on Thursday, March 27th. They issued an “overweight” rating and a $7.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Tuesday, March 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research note on Wednesday, April 9th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Mereo BioPharma Group currently has a consensus rating of “Buy” and an average price target of $7.71.

Mereo BioPharma Group Stock Up 4.4 %

MREO stock opened at $2.61 on Tuesday. Mereo BioPharma Group plc has a twelve month low of $1.58 and a twelve month high of $5.02. The stock’s 50 day moving average is $2.35 and its 200-day moving average is $3.15. The firm has a market capitalization of $414.99 million, a PE ratio of -43.50 and a beta of 0.71.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03). On average, equities research analysts anticipate that Mereo BioPharma Group plc will post -0.03 earnings per share for the current fiscal year.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.